The paramyosin (Pmy) protein has been presented as a potential vaccine candidate against Schistosoma spp. However, it remains elusive whether it works in controlling cystic echinococcosis (CE), which is caused by the larval stages of Echinococcus granulosus (E. granulosus). This study investigated the characteristics of E. granulosus Pmy (EgPmy) using in silico analysis and evaluated its potential as an epitope vaccine. The secondary structure was predicted by SOPMA software and linear B-cell epitopes were screened by the Kolaskar and Tongaonkar's method on IEBD while conformational B-cell epitopes were predicted by the Ellipro. Additionally, the epitopes of cytotoxic T lymphocyte (CTL) were analyzed by the NetCTL-1.2 server. The results showed that α-helices, extended strands, random coils and β-turns accounted for 84.82 %, 6.60 %, 5.56 % and 3.01 % in EgPmy's secondary structure, respectively. A total of 29 linear B-cell epitopes and 6 conformational epitopes were identifi ed together with 25 CTL epitopes. The CTL epitope 709 KLEEAEAFA 717 showed a high potential to elicit CTL response. These results suggested that EgPmy has a strong immunogenicity, which could serve as a reference for the development of EgPmy-based epitope vaccine against CE.
Introduction
Cystic echinococcosis (CE) is a zoonotic disease caused by infection with the larval stages of Echinococcosis granulosus (E. granulosus) . It has a worldwide distribution including Asia, Africa, Europe and North American (Eckert et al., 2000; Nunnari et al., 2012) . In China, it is mainly endemic in pasture areas such as Tibet, Xinjiang, Gansu, Qinghai, Ningxia and semi-pasture areas. The disease does great harm to human health and the development of the local economy (Yang et al., 2015) . At present, many actions have been taken to treat this disease, during which surgery in combination with medications remains the fi rst choice. However, it inevitably entails surgical risk and requires considerable labour, material, and fi nancial resources (Nasrieh et al., 2003) . Moreover, surgery often causes inevitable damage to human body and the secondary infection rate is still high. Therefore, it is still necessary to seek high-effi ciency treatment measures to control the disease. In recent years, immunoprophylaxis has become the dominant way to prevent and control echinococcosis and the advances in vaccine development have been documented. A study by Lightowlers et al. (1996) revealed that the Eg95 recombinant antigen induced a 95 -100 % protective immune effect against oncosphere infection in sheep. Siles et al. (2003) used the Em14-3-3 recombinant protein to vaccinate mice infected by the eggs of Echinococcus multilocularis (E. multilocularis), reducing the number of liver lesions in vaccinated animals from 43 to 1 mean lesion per animal.
Additionally, the Emy162 recombinant antigen showed a 74.3 % protective rate in rats against E. multilocularis (Kouguchi et al., 2011) and a vaccine against this parasite based on the Em95 protein, with a protective effi ciency of 78.5 -82.9 %, was developed by Katoh et al (2008) . These results suggested that it is feasible and effi cient to prevent echinococcosis by developing molecular vaccines. Paramyosin (Pmy) is a structural protein in invertebrate muscles (Cohen, 1982) , which involves in muscle physiological contraction and immune-regulation (Gobert & McManus, 2005) . Interestingly, it has been demonstrated to be a promising vaccine candidate for controlling the infections of both Schistosoma japonicum (S. japonicum) and S. mansoni (Jiz et al., 2015) . Also, a study by Nanduri et al. (1989) revealed that immunizing mice with the Caenorhabditis elegans paramyosin protects against Brugia malayi challenge with an immune protective effect of up to 60 %. Moreover, Vazquez et al. (2001) discovered that the parasite load in mice infected with Taenia solium (T. solium) larvae is reduced by approximately 52 % by immunizing mice with the total length of T. solium recombinant paramyosin. In addition, Ferrer et al. (2003) reported that the T. saginata paramyosin was highly recognized by antibodies in 100 % of the sera collected from patients with acute cysticercosis. However, little information is known about their protection effi ciency as vaccines against CE. The fi nding attracts us to study the protection role of E. granulosus Pmy (EgPmy) against the parasite infection, since that EgPmy shares a high identity to that of S. mansoni, and is also expressed in the tegument of the larval cestode (Mühlschlegel et al., 1993) . Previous studies have suggested that the protein was relevant to immuno-regulatory events at the host-parasite interface a nd the detection of its IgG4 was found to show a good diagnostic potential of human hydatidosis (Monteiro et al., 2010; Moghadam et al., 2013) . What's more, EgPmy was reported to share some sequence elements and properties with EgA31, the latter protein was demonstrated to induce a high efficient protection against E. granulosus infection in dogs (Petavy et al., 2008) . Overall, th ese results implied a potential of EgPmy to be an immunogen and vaccine target against CE. With the advance of bioinformatics technology, the epitope vaccine has become a hot area in vaccine development (Ben & Arnon, 2005; Pfaff et al., 1988; Toussaint & Kohlbacher, 2009; Zieglmayer et al., 2016; Oyarzún & Kobe, 2016) . Compared to traditional vaccines, epitope vaccines have the ability to stimulate an effective specifi c immune response with a minimal structure, while avoiding undesirable effects (Ben & Arnon, 2005) . Considering that EgPmy is a macromolecular protein with 97-kDa (Cohen, 1982) , a minimal molecular weight with the main immunogenic epitopes of EgPmy, should induce a more specifi c antibody response but less side effects. However, it is still unclear whether the EgPmy could be developed to design an epitope vaccine. In this study, we used in silico analysis to characterize the secondary structure, the B-cell and CTL epitopes in EgPmy, which would provide the theoretical foundation for developing EgPmy-based epitope vaccine.
Materials and Methods

Protein sequence retrieval
The nucleotide sequence of EgPmy was retrieved from GenBank (GenBank No. Z21 787). A t otal of 863 amino acid residues were predicted in EgPmy protein, and were then used as an template for analyzing its antigenicity, secondary structure, as well as epitopes. The amino acid sequence of EgPmy was shown in Supplementary  Fig. 1 .
Structural analysis
Various parameters for EgPmy, including the molecular weight, theoretical pI, atomic composition, instability index, aliphatic index and grand average of hydropathicity (GRAVY), were predicted by the Pr otParam (htt p://web.expasy.org/protparam/) (Gasteiger et al., 2005) . To determine its antigenicity, the parameters of the secondary structure that include α-helices, extended strands, β-turns and random coils, were analyzed by the improved self-optimized prediction method (SOPMA) software (http://npsa-pbil.ibcp.fr/ cgi-bin/npsa_automat.pl?page=npsa_sopma.html) (Geourjon & Deléage, 1995) . The protein sequence was input, and the parameters of similarity threshold and window width were set to 8 and 17, respectively, while other parameters were not adjusted.
B-cell epitope prediction
Linear B-cell epitopes of EgPmy were predicted at the Immune Epitope Database (IEDB: http://tools.immuneepitope.org/bcell/) online software (Vita et al., 2010) using the method of Kolaskar and Tongaonkar (Kolaskar & Tongaonkar, 1990) , which is based on the occurrence of amino acid residues in experimentally determined epitopes. The method was applied to predict antigenic determinants on a large number of proteins with about 75 % accuracy, which is much better than most of the known methods (Kolaskar & Tongaonkar, 1990) . Moreover, Emini's method (Emini et al., 1985) was used for surface accessibility prediction while Karplus and Schulz's algorithm (Vihinen et al., 1994) for fl exibility determination. Conformational B-cell epitopes based on the protein antigen's 3D structure were predicted by an online tool Ellipro (http://too ls.immuneepitope.org/ellipro/) (Ponomarenko et 2008). The input fi le of EgPmy to the online tool was provided in PDB format and the minimum score value was set at 0.7 while the maximum distance was selected as 6 Å.
CTL epitopes prediction CTL epitope prediction was carried out using the NetCTL.1.2 server (http://www.cbs.dtu.dk/services/NetCTL) (Larsen et al., 2007) . The method combines the prediction of peptide major histocompatibility complex (MHC) class I binding, proteasomal C terminal cleavage and T cell activating protein (TAP) transport effi ciency. MHC class I binding and proteasomal cleavage are performed using artifi cial neural networks and TAP transport effi ciency is predicted using weight matrix (Larsen et al., 2007) . The input fi le for EgPmy was provided with the protein sequence and the parameter of MHC class I supertype was selected as A2. The remaining parameters were not altered. Therefore, the IEDB online prediction software (http://tools.immuneepitope.org/Immunogenicity/) (Calis et al., 2013) was applied to predict the immunogenicity of the candidate epitopes. This tool uses amino acid properties as well as their position within the peptide to predict the immunogenicity of a peptide-MHC (pMHC) complex (Calis et al., 2013) .
Results
Structure characteristics
To understand the antigenic features, the secondary structural Fig. 1 ). The grand average of GRAVY was predicted to be negative (-0.897) . This showed that the protein has a good hydrophilicity and most of the residues are located on the surface, which are likely to bind residues when interacting with other proteins (Kyte & Dool ittle, 1982) .
B-cell epitopes identifi cation
The identifi cation of B-cell epitope is one of the key steps in the development of an epitope vaccine. This study predicted the B-cell epitopes of EgPmy using the IEDB software, and EgPmy was found to contain 29 linear B-ce ll epitopes. Their length ranged from 6 to 20 amino acids with 6 octapeptides and 7 heptapeptides. The epitope length, sequences and locations, were shown in Table 2. The antigenic propensity varied along the sequence length, and the average antigenic propensity value of these epitopes was 0.992 with a minimum of 0.868 and a maximum of 1.159 (Supplementary Fig. 2) . Moreover, surface accessi bility and fragment fl exibility, the important features of B-cell eptitopes, were also analyzed by IEDB database. According to Emini's method, the maximum surface accessibility value of the predicted epitopes was 5.287 from amino acid position 754 to 759 for EgPmy. Fig. 3 ). On the other hand, the result of the fl exibility prediction showed that the maximum value of the fl exibility was 1.142 from amino acid position 67 to 72 for EgPmy. The sequence of the heptapeptide was 67 GTSSQTQ 72 , where 70S was the fl exibility residue. The minimum fl exibility value was 0.917 from amino acid position 277 to 283 and its sequence of the heptapeptide was 277 NADMAAL 283 , where 280M was the fl exibility residue (Supplementary Fig. 4) . In addition, 6 conformational B-cell epitopes were obtained by the ElliPro with a score defi ned as a Protrusion Index (PI) value over 0.7. The highest probability of a conformational epitope was calculated at 98.7 % (PI score: 0.987). Conformational epitopes' residues, their sequence location, number of residues and scores were given in Table 3 .
No.
Residues G741, E742, I743, R745, A746, K747, E768, D769, D770,  K771, R772, M773, I774, L775, E776, L777, Q778, D779,  L780, L781, D782, K783, T784, Q785, I786, K787, M788,  K789, A790, Y791, K792, R793, Q794, L795, E796, E797,  Q798, E799, E800, V801, S802, Q803, L804, T805, M806,  S807, K808, Y809, R810, K811, A812, Q813, Q814, Q815,  I816, E817, E818, A819, E820, H821, R822, A823, D824,  M825, A826, E827, R828, T829, I830, T831, I832, K833, T835,  I836, G837, G838, P839, G840, S841, R842, A843, V844,  S845, V846, V847   94  0.753   5  G398, Q399, V400, G401, D402, L403, T404, D405, R406,  I407, A408, N409, L410, D411, R412, E413, N414, R415, A431,  N432, R433, R434, L435, T436, D437, E439, A440, L441,  R442, S443, Q444, L445, E446, A447, D448, G449, D450,  N451, L452, A453, S454, A455, L456, H457, D458, A459,  E460, E461, A462, L463, K464, E465, L466, E467, V468,  K469, Y470, V471, A472, S473, Q474, N475, A476   63  0.741   6  S214, K215, T216, K217, S218, V219, L220, E221, G222,  Q223, L224, D225, D226, L227, K228, K613, N614, A615,  E616, S617, E618, L619, N620, D621, A622, N623, G624,  R625, I626, S627, E628, L629, T630, M631, A679, D680,  E681, L682, R683, Q684, E685, Q686, E687, N688, Y689,  K690 46 0.707 Table 3 . Predicted conformational B-cell epitopes of EgPmy using the Ellipro. Table 4 . Predicted CTL epitopes of EgPmy using NetCTL-1.2 software.
CTL epitopes identifi cation CTL epitopes were predicted using NetCTL.1.2 server prediction tool. Protein sequence was predicted based on their MHC binding affi nity, proteasomal C-terminal cleavage, and transport affi nity. Prediction was performed using MHC supertype A2. Twenty-fi ve peptides with 9-mer sequence, whose prediction scores were over 0.75000, were identifi ed as CTL epitopes (Shown in Table 4 ). Then, these peptide sequences were submitted for MHC Class I immunogenicity prediction. Most of them showed high scor e of immunogenicity to activate and elicit CTL's effector functions (Table 4) .
Discussion
Pmy has been demonstrated to be a promising vaccine candidate for control of S. japonicum, S. mansoni (Jiz et al., 2015) , Brugia malayi (Nanduri et al., 1989) , T. solium (Vazquez et al.2001) and T. saginata (Ferrer et al., 2003) infections. These results implied a potential of EgPmy to be an effective vaccine against CE. In order to lay the basis for the development of the EgPmy-based epitope vaccine to control and prevent cystic echinococcosis, the in silico analysis was performed to probe the secondary structures, B-cell and CTL epitopes of the EgPmy protein.
The α-helices and extended strands are very common structures and located inside the secondary structure of proteins, which cannot be changed easily. The α-helices and extended strands accounted for 84.82 % and 6.60 % in EgPmy, indicating a good stability of the protein. On the contrary, the random coils and β-turns often appear on the protein surface and have the potential to form epitopes (Li et al., 2013) . The proportions of the random coils and β-turns were 5.56 % and 3.01 % in EgPmy, respectively. These regions are likely to form epitopes. A key process of epi t ope vaccine preparation is to obtain useful epitopes (Li et al., 2013) . Epitopes can be divided into B-and T-cell epitopes. B-cell epitope is a binding site of an antibody on an antigen, and accurate epitope identifi cation is essential to developing epitope vaccines (Ren et al., 2014) . To improve the accuracy of the B-cell epitope prediction, multi-parameter analysis was utilized in this study. The surface accessibility area analysis showed that the residues on the surface of EgPmy, might contact with the solvent molecules. The fl exibility parameter prediction refl ected the ability of the protein to fold and bend and the antigenic propensity analysis demonstrated the immunogenic regions of the antigen protein (Kolaskar & Tongaonkar, 1990; Emini et al., 1985; Vihinen et al., 1994) . In this study, 29 linear B-cell epitopes were identifi ed for EgPmy with the high antigenic property. Notably, 754 RKYERQ 759 and 67 GTSSQTQ 72 showed a high value of surface accessibility and fragment fl exibility, respectively, which might suggested that the residues were the most likely vital epitopes that can be used to develop EgPmy-based epitope vaccine. However, it is worth noting that some epitopes, due to the restriction of complicated 3D structure, are shielded by the outer layer of the protein, which is called conformation epitope. This study also predicted 6 conformational epitopes in EgPmy. Overall, a total of 35 B-cell epitopes were found in EgPmy, which indicated a strong immunogenicity of this protein.
CTLs can destroy infected cells, and their activation takes place on the surface of antigen-presenting MHC molecules (Larsen et al., 2007) . Hence, reliable prediction of CTL epitopes is a vital step for designing epitope-driven vaccine. In T-cell epitope prediction, the accuracy rate of the MHC-I epitope prediction has been demonstrated to be as high as 90 % (Testa et al., 2012) . However, it is restricted by human leukocyte antigen (HLA) proteins which is highly polymorphic in diverse ethnic populations (Maenaka & Jones, 1999; Stern & Wiley, 1994) . Yan et al (2003) found that the MHC-I HLA-A*0201-restricted T-cell epitopes are common in Chinese Han people. Therefore, this study analyzed the HLA-A*0201-restricted CTL epitopes in EgPmy, and 25 high score CTL epitopes were identifi ed, which might be of great use to develop epitope vaccine.
In conclusion, this s tudy analyzed the secondary structure, B-cell and CTL epitopes in EgPmy. Twenty-nine linear B-cell epitopes, 6 conformation epitopes and 25 CTL epitopes were identifi ed as the potential dominant epitopes. Moreover, the CTL epitope 709 KLEE-AEAFA 717 showed a high potential to elicit a CTL response. Overall, the results would provide the basis for the preparation of the EgPmy-based epitope vaccine against CE.
